Bamco Inc Aerie Pharmaceuticals Inc Transaction History

Bamco Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 18, 2020	SELL	$17.72 - $25.1 $2.5 Million - $3.54 Million	-141,194 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$18.41 - $28.0 $2.47 Million - $3.75 Million	-134,032 Reduced 48.7%	141,194 $2.71 Million
Q2 2019 Aug 15, 2019	BUY	$28.97 - $48.21 $6.38 Million - $10.6 Million	220,263 Added 400.75%	275,226 $8.13 Million
Q1 2019 May 15, 2019	BUY	$36.32 - $49.25 $372,352 - $504,911	10,252 Added 22.93%	54,963 $2.61 Million
Q4 2018 Feb 14, 2019	BUY	$33.0 - $60.04 $47,817 - $86,997	1,449 Added 3.35%	44,711 $1.61 Million
Q3 2018 Nov 14, 2018	BUY	$56.15 - $73.9 $1.02 Million - $1.34 Million	18,194 Added 72.58%	43,262 $2.66 Million
Q2 2018 Aug 14, 2018	BUY	$47.85 - $70.45 $492,807 - $725,564	10,299 Added 69.73%	25,068 $1.69 Million
Q1 2018 May 09, 2018	BUY	$51.15 - $61.0 $379,430 - $452,498	7,418 Added 100.91%	14,769 $801,000
Q4 2017 Feb 14, 2018	BUY	$50.85 - $65.1 $60,765 - $77,794	1,195 Added 19.41%	7,351 $439,000
Q3 2017 Nov 15, 2017	BUY	$48.6 - $60.1 $299,181 - $369,975	6,156	6,156 $299,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Bamco Inc , based on Form 13F filings with the SEC.

Stay updated on Bamco Inc with notifications on news.